Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in inflammatory Bowel Disease

• Type: Article in International Scientific Journal
• Date: 2020

Authors

Pinto Lopes, P (Author) Other; Afonso, J (Author) Other; Pinto Lopes, R (Author) Other; Rocha, C (Author) Other; Lago, P (Author) Other; Goncalves, R (Author) Other; De Sousa, HT (Author) Other; Macedo G (Author) FMUP; Dias C (Author) FMUP; Magro F (Author) FMUP

Journal

Title: Inflammatory Bowel Diseases

Vol. 26

Pages: 1707-1719

ISSN: 1078-0998

Publisher: Oxford University Press

Indexing

ISI Web of Knowledge - 16 Citations

Scopus - 15 Citations

Other information

Authenticus ID: P-00T-0KM

DOI: 10.1093/ibd/izz319

Abstract (EN): Background: Serum dipeptidyl peptidase 4 (DPP-4) has drawn particular interest as a biomarker in inflammatory bowel disease (IBD), as this protease inactivates several peptides that participate in the inflammatory cascade. Method& Two prospectively recruited cohorts consisting of 195 patients (101 had Crohn's disease [CD] and 94 had ulcerative colitis [UC]) were evaluated using clinical indexes and followed up to assess for treatment escalation. Sixty-eight patients underwent endoscopic evaluation at baseline. In the second cohort of 46 biologically treated patients, treatment response was assessed. Serum DPP-4, C-reactive protein (CRP), and fecal calprotectin levels were quantified at baseline and during follow-up. Results: Median DPP-4 levels were significantly lower in active IBD patients when compared with remitters (CD: 1043 [831-1412] vs 1589 [1255-1956] ng/mL; P < 0.001; UC: 1317 [1058-1718] vs 1798 [1329-2305] ng/mL; P = 0.001) and healthy controls (2175 [1875-3371] ng/mL). In fact, DPP-4 was able to distinguish clinical and endoscopic activity from remission, with areas under the curve (AUC) of 0.81/0.93 (CD) and 0.71/0.79 (UC), along with the need for treatment escalation, with comparable AUCs of 0.79 (CD) and 0.77 (UC). Furthermore, DPP-4 levels were higher in responders to treatment and more pronounced among UC (1467 [1301-1641] vs 1211 [1011-1448] ng/mL; P < 0.001) than CD patients (1385 [1185-1592] vs 1134 [975-1469] ng/mL; P = 0.015). Conclusions: Our results suggest that serum DPP-4 can be used as a noninvasive biomarker of IBD activity and biological treatment response and a predictor of treatment escalation, particularly when combined with other biomarkers.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13